Business Context and Reporting Period
This Form 8-K Current Report was filed by Assembly Biosciences, Inc. on January 10, 2017, covering events occurring on January 6, 2017. The filing details the entry into a Material Definitive Agreement with Allergan Pharmaceuticals International Limited to develop and commercialize select microbiome gastrointestinal programs.
Key Financial Metrics and Transaction Terms
The Collaboration Agreement includes the following financial terms:
- Upfront Payment: $50 million payable by Allergan to the Company.
- Development Milestones: Up to approximately $630 million contingent on successful development.
- Commercial Milestones: Up to approximately $2.15 billion contingent on successful commercialization for up to six indications.
- Royalties: Tiered rates ranging from mid-single digits to mid-teens based on net sales.
- Cost Sharing: Development costs up to $75 million through proof-of-concept (POC) studies are shared on a 2/3 (Allergan) and 1/3 (Company) basis. Allergan assumes all post-POC costs.
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics for the Company.
Material Changes and Agreements
The primary material change is the execution of the Research, Development, Collaboration and License Agreement. Key operational changes include:
- Granting Allergan an exclusive worldwide license for intellectual property related to ulcerative colitis, Crohn's disease, and irritable bowel syndrome.
- Establishment of a joint research and development plan.
- Option for the Company to co-promote licensed programs in the United States and China.
- Provisions for termination by Allergan for convenience with 90 or 120 days' notice depending on trial status.
Outlook, Risks, and Contingencies
Outlook and Closing: The transaction is expected to close in the first quarter of 2017, subject to customary conditions including the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period.
Risks and Contingencies:
- Termination Risk: Allergan may terminate the agreement for convenience.
- Cost Overruns: If pre-POC costs exceed $75 million, the Company must either fund 1/3 of the excess or allow Allergan to deduct 1/3 of the excess plus a 25% premium from future milestone payments.
- Regulatory: Closing is contingent on antitrust review.
Investor Verification Checklist
- Verify the closing date of the transaction and receipt of the $50 million upfront payment.
- Confirm the specific indications covered under the six potential commercial milestones.
- Monitor the status of the Hart-Scott-Rodino waiting period.
- Review the specific terms regarding the co-promotion option in the U.S. and China.
- Assess the impact of the 25% premium deduction clause on future milestone valuations if development costs exceed $75 million.